Eileen K. Sawyer

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Annette von Drygalski, Adam Giermasz, Giancarlo Castaman et al. · Blood Advances · 2019 · 135 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys

Thomas J. Weber, Eileen K. Sawyer, Scott Moseley et al. · Metabolism · 2016 · 103 citations

Medicine, Hematology, Geriatrics +3

Evidence of a disability paradox in patient‐reported outcomes in haemophilia

Jamie O’Hara, Antony P. Martin, Diane J. Nugent et al. · Haemophilia · 2021 · 64 citations · Full text

Pharmacy, Health Sciences, Health Assessment +16

World Federation of Hemophilia Gene Therapy Registry

Barbara A. Konkle, Donna Coffin, Glenn F. Pierce et al. · Haemophilia · 2020 · 51 citations · Full text

Medicine, Biotechnology, Hematology +10

Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys

Tom Burke, Sohaib Asghar, Jamie O’Hara et al. · Orphanet Journal of Rare Diseases · 2021 · 41 citations · Full text

Medicine, Hematology, Pharmacoeconomics +17